The Pill that
moves the needle®
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform.
We have proprietary technology, partnerships to accelerate our development, and an experienced team with deep industry expertise.
Our Mission
From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases.
We are dedicated to advancing vaccine science to create safe, effective, and accessible solutions that protect communities worldwide and empower people to lead healthier lives.
Our Science
Vaxart’s oral pill vaccines are designed to generate durable mucosal and systemic immunity, offering a potentially revolutionary advance in immunization technology.
VAXART News
-
Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
-
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
-
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
See News and SEC Filings for additional important information.